Clinical Trials

390 enrolled

Ovarian Neoplasms

NCT06787612 2026-04-08

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

220 enrolled

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

72 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05489211 2026-03-19

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

GastrointestinalGynecologic

454 enrolled

Biliary Tract Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04931342 2026-03-10

BOUQUET

176 enrolled

Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02884648 2026-02-06

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

35 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07370818 2026-01-27

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

81 enrolled

Ovarian Neoplasms

NCT07340164 2026-01-14

TROY

116 enrolled

Ovarian Neoplasms, Recurrence

NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

38 enrolled

Ovarian Neoplasms

NCT02364713 2025-12-11

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Phase 2 Terminated

17 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07059845 2025-12-04

FLORENZA

320 enrolled

Ovarian Neoplasms

NCT05446870 2025-10-01

MK-4830-002

160 enrolled 19 charts

Ovarian Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

77 enrolled 8 charts

Ovarian Neoplasms

NCT06540729 2025-07-08

DAB

39 enrolled

Ovarian Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT05044871 2025-06-08

BRIGHT

108 enrolled

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

7 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06735326 2024-12-16

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

105 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02312245 2024-12-05

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

13 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT04787289 2024-08-07

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

244 enrolled

Ovarian Neoplasms

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT02923739 2024-03-13

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Terminated

9 enrolled 9 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

44 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05751629 2023-04-21

COHORT-A

41 enrolled 17 charts

Ovarian Neoplasms

NCT05819060 2023-04-19

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

44 enrolled

Ovarian Neoplasms

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

122 enrolled

Ovarian Neoplasms

NCT04753216 2023-01-19

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

3 enrolled 15 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01097746 2022-10-28

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

33 enrolled 10 charts

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05551208 2022-09-22

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

42 enrolled

Ovarian Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

35 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05310344 2022-04-04

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

50 enrolled

Ovarian Neoplasms

NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

150 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05170594 2021-12-28

A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

60 enrolled

Ovarian Neoplasms

NCT01551745 2021-10-19

Salvage Ovarian FANG™ Vaccine + Bevacizumab

5 enrolled 9 charts

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02853318 2021-10-06

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

40 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02022917 2021-01-27

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

22 enrolled

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02399592 2020-11-30

Toco-Ovar

23 enrolled

Ovarian Neoplasms

NCT00436215 2020-11-23

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

55 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04556071 2020-11-10

AVANIRA3

32 enrolled